版本:
中国

BRIEF-Merrimack Pharma estimates will incur charges for one-time termination benefits in connection with corporate restructuring of about $4.5-$5.5 mln

Oct 3 Merrimack Pharmaceuticals Inc

* Reduction in headcount will not impact company's commercial team or execution of ONIVYDE'S commercial launch and label expansion

* Estimates will incur charges for one-time termination benefits in connection with corporate restructuring of about $4.5-$5.5 million Source text: [bit.ly/2dDBdCm] Further company coverage:

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐